Sarepta Therapeutics knew about the death of a patient treated with its experimental gene therapy for a type of limb-girdle muscular dystrophy, but said nothing public for a month. Financial analysts lambasted Sarepta executives for failing to disclose the fatality when the company announced a restructuring that includes stopping work on this limb-girdle program.
The post Sarepta CEO: ‘We Have, I Believe, a Very Laudable History of Being Extraordinarily Transparent’ appeared first on MedCity News.
